CN101389334A - 埃坡霉素d的给药方法 - Google Patents

埃坡霉素d的给药方法 Download PDF

Info

Publication number
CN101389334A
CN101389334A CNA03815062XA CN03815062A CN101389334A CN 101389334 A CN101389334 A CN 101389334A CN A03815062X A CNA03815062X A CN A03815062XA CN 03815062 A CN03815062 A CN 03815062A CN 101389334 A CN101389334 A CN 101389334A
Authority
CN
China
Prior art keywords
epothilone
experimenter
venoclysis
treatment cycle
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA03815062XA
Other languages
English (en)
Chinese (zh)
Inventor
R·G·小约翰逊
M·谢里尔
A·汉南
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kosan Biosciences Inc
Original Assignee
Kosan Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kosan Biosciences Inc filed Critical Kosan Biosciences Inc
Publication of CN101389334A publication Critical patent/CN101389334A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA03815062XA 2002-05-20 2003-05-20 埃坡霉素d的给药方法 Pending CN101389334A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38216602P 2002-05-20 2002-05-20
US60/382,166 2002-05-20

Publications (1)

Publication Number Publication Date
CN101389334A true CN101389334A (zh) 2009-03-18

Family

ID=33476529

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA03815062XA Pending CN101389334A (zh) 2002-05-20 2003-05-20 埃坡霉素d的给药方法

Country Status (7)

Country Link
US (1) US20040072882A1 (enExample)
EP (1) EP1575556A2 (enExample)
JP (1) JP2006514681A (enExample)
KR (1) KR20050043796A (enExample)
CN (1) CN101389334A (enExample)
AU (1) AU2003296878A1 (enExample)
WO (1) WO2004103267A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001124A1 (en) * 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
ATE350383T1 (de) * 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
BRPI0414043A (pt) * 2003-09-02 2006-10-24 Novartis Ag tratamento de cáncer com epotilonas
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20050215604A1 (en) * 2004-03-26 2005-09-29 Kosan Biosciences, Inc. Combination therapies with epothilones and carboplatin
US7754850B2 (en) 2005-02-11 2010-07-13 University Of Southern California Chimeric disintegrin domain
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
EP2279285B1 (en) 2008-04-25 2015-02-11 ASM International N.V. Synthesis and use of precursors for ald of tellurium and selenium thin films
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
KR101829380B1 (ko) 2009-10-26 2018-02-19 에이에스엠 인터내셔널 엔.브이. ５ａ족 원소 함유 박막의 원자 층 증착용 전구체의 합성 및 용도
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189698B1 (pl) * 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
WO1999001124A1 (en) * 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
ATE250066T1 (de) * 1997-12-04 2003-10-15 Bristol Myers Squibb Co Verfahren zur reduktion von oxiranyl-epothilonen zu olefinischen epothilonen
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
CN100381566C (zh) * 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
US6664288B1 (en) * 1999-04-14 2003-12-16 Dana Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
JP2004500388A (ja) * 2000-03-01 2004-01-08 スローン−ケッタリング　インスティトュート　フォア　キャンサー　リサーチ エポチロン、その中間体およびその類似体の合成
DK1652926T3 (da) * 2000-04-28 2010-02-15 Kosan Biosciences Inc Krystallinsk epothilon D
WO2002008440A2 (en) * 2000-07-25 2002-01-31 Kosan Biosciences, Inc. Fermentation process for epothilones

Also Published As

Publication number Publication date
WO2004103267A3 (en) 2008-11-27
JP2006514681A (ja) 2006-05-11
KR20050043796A (ko) 2005-05-11
EP1575556A2 (en) 2005-09-21
US20040072882A1 (en) 2004-04-15
AU2003296878A1 (en) 2004-12-13
WO2004103267A2 (en) 2004-12-02
AU2003296878A8 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
EP2127652B1 (en) Method for treating cancer using anticancer agent in combination
US20200281921A1 (en) Cancer treatment with combination of plinabulin and taxane
CN101389334A (zh) 埃坡霉素d的给药方法
US20230235083A1 (en) Combination therapy using a liv1-adc and a chemotherapeutic
Gadgeel et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design
Stevenson et al. Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days
JP2016528217A (ja) 低酸素活性化プロドラッグおよびタキサンの組合せを用いた膵臓癌の治療
JP2009527505A (ja) 抗癌用途のためのドキソルビシン製剤
US20250011470A1 (en) Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
JP7115671B2 (ja) 新規なｍｃｔ４阻害剤及びその使用
UA126029C2 (uk) Фармацевтичні комбінації для лікування раку
JP2012526089A (ja) カバジタキセルおよびカペシタビンを含む抗腫瘍性組み合わせ
Villalona-Calero et al. Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies
EP1206256B1 (en) Combination therapy using pentafluorobenzenesulfonamide and platin compound
WO2020192506A1 (zh) 西奥罗尼用于小细胞肺癌的治疗
Monk et al. A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors
US20250302813A1 (en) Recombinant methioninase in the treatment of cancer
Juergens et al. Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter
McEntee et al. Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs
JP2005255643A (ja) 抗腫瘍効果増強方法および抗腫瘍効果増強剤
Posner Clinical pharmacology–the basics
CN120417941A (zh) 治疗非霍奇金淋巴瘤的药物组合及其用途
US20220071982A1 (en) Methods and uses for treating cancer
Pouessel et al. PHASE II STUDY OF TLN-232∗, A NOVEL M2PK TARGETING AGENT, ADMINISTERED BY CIV TO PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)
WO2023039568A1 (en) Therapeutic combinations of orally administered paclitaxel, a p-gp inhibitor, and a checkpoint inhibitor for the treatment of solid tumors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090318